Zobrazeno 1 - 8
of 8
pro vyhledávání: ''
Autor:
Melanie Boerries, Oliver Thomusch, Michael Rassner, Matthias Kroiss, Paul la Rosee, Juri Ruf, Konrad Aumann, Cornelius Miething, Christine Dierks, Patrick Metzger, Tilmann Schumacher, Nikolas von Bubnoff, Selina Kiefer, Katharina Laubner, Christian Weißenberger, Claudius Klein, Andreas Zielke, Harald Weiss, Constantin Smaxwil, Justus Duyster, Philipp T. Meyer, Jochen Seufert
Publikováno v:
Thyroid
Background: Anaplastic thyroid carcinoma (ATC) and metastatic poorly differentiated thyroid carcinomas (PDTCs) are rare aggressive malignancies with poor overall survival (OS) despite extensive multimodal therapy. These tumors are highly proliferativ
Autor:
Min Ji Jeon, Young Kee Shong, Meihua Jin, Jonghwa Ahn, Tae Yong Kim, Dong Eun Song, Sang-Yeob Kim, Yeon-Mi Ryu, Won Bae Kim, Eyun Song, Won Gu Kim
Publikováno v:
Thyroid. 31:61-67
Background: Advanced thyroid cancers, including differentiated thyroid carcinoma (DTC) with distant metastasis, and anaplastic thyroid carcinoma (ATC), are associated with poor clinical outcomes an...
Publikováno v:
Thyroid
Background: Thyroid immune-related adverse events (IRAEs) have been reported more frequently with programmed cell death protein-1 (PD-1) inhibitors than cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors, but there is limited data describing endocr
Autor:
Qinghai Ji, Yu-Long Wang, Cui-Wei Li, Wen-Jun Wei, Ben Ma, Rong-Liang Shi, Peng-Cheng Yu, Li-Cheng Tan, Bo-Wen Lei, Jia-Qian Hu, Yu Wang, Nai-Si Huang, Yan Zhang, Weibo Xu, Xiao Shi, Tong-Zhen Chen, Xiao Wang, Jie Wang
Publikováno v:
Thyroid. 29:1269-1278
Background: Expression of the programmed death-ligand 1 (PD-L1) in medullary thyroid carcinoma (MTC) has been rarely reported. In this study, we evaluated PD-L1 positivity in MTC and analyzed its c...
Autor:
Leila Shobab, Cristiane Gomes-Lima, Leonard Wartofsky, Kenneth D. Burman, Alexander Zeymo, Rebecca Feldman, Jacqueline Jonklaas
Publikováno v:
Thyroid. 29:1262-1268
Background: Six to 20% of thyroid cancer (TC) patients develop distant metastases, and one-third become radioiodine refractory (RAIR). Available targeted therapies increase progression-free surviva...
Autor:
Jonghwa Ahn, Dong Eun Song, Won Gu Kim, Min Ji Jeon, Young Kee Shong, Tae Yong Kim, Eyun Song, Hye-Seon Oh, Won Bae Kim
Publikováno v:
Thyroid. 29:824-829
Background: The lymphocyte-to-monocyte ratio (LMR), which reflects the tumor-infiltrating immune cell status and host immunity, has been reported as a prognostic marker in various cancers. The aim ...
Autor:
Yuji Sakuma, Tetsuo Kondo, Mitsuyo Yoshihara, Shoichi Matsukuma, Munetake Masuda, Hiroyuki Hayashi, Naoyuki Okamoto, Yohei Miyagi, Akira Yoshida, Michiko Fukahori, Shiro Koizume
Publikováno v:
Thyroid. 22:683-689
Many studies on thyroid follicular tumors have reported the presence of somatic mutations to three forms of RAS: HRAS, KRAS, and NRAS. However, the frequency and clinical significance of these RAS mutations remain unclear, in large part due to the di
Autor:
Philipp le Coutre, Ulrich Schweizer, Jörg Westermann, Renate Arnold, Theo D. Kim, Michaela Schwarz, Ursula Plöckinger, Doreen Braun, Peggy Grille, Hendrik Nogai, Bernd Dörken
Publikováno v:
Thyroid. 20:1209-1214
BACKGROUND: Thyroid dysfunction is a well-known adverse effect of first-generation tyrosine kinase inhibitors (TKIs), like sunitinib. The aim of this study was to investigate the effect of second-generation TKIs on thyroid function. METHODS: We retro